This report highlights key achievements registered by the Ministry of Health, affiliated institutions, implementing agencies both at central and decentralized levels in 2013-2014. Generally, the Health Sector accomplishments and programs routine data for 2013-2014 confirm that Rwanda maintains its p...rogress towards the realization of health-related MDGs and national health targets as well.
more
Issue Brief no. 16. 20 Sept 2021.
Many studies have shown the effectiveness of vaccination against COVID-19 and that it protects against severe
illness. A high vaccination rate is needed to combat... the pandemic worldwide. Due to misinformation and myths,
there is still a great hesitancy to vaccinate . With this Issue Brief, we would like to present various myths and provide
you with educational materials on the respective topics for communication in the MEDBOX
more
MEDBOX Dossier no. 16. 28 Sept 2021.
De nombreuses études ont montré l'efficacité de la vaccination contre le COVID-19 et le fait qu'elle protège contre les maladies graves.
maladie grave. Un taux de ...>vaccination élevé est nécessaire pour combattre la pandémie dans le monde entier. En raison de la désinformation et des mythes, les gens hésitent encore beaucoup à se faire vacciner. Dans ce dossier, nous souhaitons vous présenter différents mythes et vous fournir du matériel éducatif sur ces sujets et vous fournir du matériel éducatif sur les sujets respectifs à communiquer dans le MEDBOX.
more
(Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та Spikevax® виробництва Moderna);
Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. ...30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
– (Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer... und Spikevax® von Moderna)
more
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...a evaluado la eficacia).Entre los participantes sin evidencia de infección previa por SARS-CoV-2, hubo 3 casos de COVID-19 entre los 1.305 receptores de vacuna a partir de los 7 días de la segunda dosis y 16 entre los 663 receptores de placebo.
more
Until fairly recently, debates about how to tackle the looming threat of antibiotic resistance have tended to focus on how to come up with new antibiotics
The tab is the result of a preliminary landscape of vaccines licensed or under development for Mpox
Las preguntas más frecuentes de padres y madres sobre la inmunización
Infórmate sobre las vacunas que más se suelen recomendar
i. A person who is a contact of a probable or confirmed mpox case in the 21 days before the onset of signs or symptoms, and who presents with any of the following: acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back pain, profound weakness or fatigue.
OR
ii. A per...son presenting since 01 January 2022 with an unexplained acute skin rash, mucosal lesions or lymphadenopathy (swollen lymph nodes). The skin rash may include single or multiple lesions in the ano-genital region or elsewhere on the body. Mucosal lesions may include single or multiple oral, conjunctival, urethral, penile, vaginal, or ano-rectal lesions. Ano-rectal lesions can also manifest as ano-rectal inflammation (proctitis), pain and/or bleeding.
AND
for which the following common causes of acute rash or skin lesions do not fully explain the clinical picture: varicella zoster, herpes zoster, measles, herpes simplex, bacterial skin infections, disseminated gonococcus infection, primary or secondary syphilis, chancroid, lymphogranuloma venereum, granuloma inguinale, molluscum contagiosum, allergic reaction (e.g., to plants); and any other locally relevant common causes of papular or vesicular rash.
more
The World Health Organization (WHO) provides a collection of case studies titled "Stories from the Field," highlighting global efforts to prevent and control noncommunicable diseases (NCDs) such as cancer, diabetes, heart, and lung diseases. These narratives showcase how various countries implement ...WHO's technical guidance to improve NCD outcomes through cost-effective and equitable interventions. The stories cover topics like integrating NCD care into primary health systems, enhancing cancer treatment accessibility, and supporting individuals with NCDs during health emergencies. By sharing these experiences, WHO aims to inspire and inform global health initiatives targeting NCDs.
more
28 Sept. 2021
The focus of this fact sheet is on the four main causes of acute bacterial meningitis:
Neisseria meningitidis (meningococcus)
Streptococcus pneumoniae (pneumococcus)
Haemophilus influenzae
Streptococcus agalactiae (group B streptococcus)
WHO practical guidelines. 2nd edition
Guide pratique à l’usage des médecins, infirmiers, techniciens de laboratoire, auxiliaires de santé et logisticiens
Practical guide for doctors, nurses, laboratory technicians, medical auxiliaries and logisticians
This position paper on polio vaccines replaces the 2016 WHO position paper, and summarizes recent developments in the field.